NEWS & MEDIA
First Patient Treated in Clinical Study of OsteoActivator-P Membranes for Accelerated Alveolar Ridge Preservation
Osteo-Pharma today announced that the first patient has been treated for the clinical trial ‘OsteoActivator-P for accelerated localized alveolar ridge preservation’. The study is a randomized prospective clinical trial, comparing OsteoActivator-P coated membranes vs Collagen Membrane-P uncoated for accelerated localized alveolar ridge preservation and will investigate the efficacy and safety of OsteoActivator-P. The study is expected to enroll a total of 16 patients at 2 clinical centers in The Netherlands.
Osteo-Pharma and Emultech announce joint venture to develop First-In-Class disease modifying treatment for Osteoarthritis
Emultech and Osteo-Pharma today announced a joint venture to develop what could be the first disease-modifying treatment for osteoarthritis of the knee.
Osteo-Pharma receives MREC approval for initiation of clinical trial
Osteo-Pharma today announced that it has successfully obtained MREC approval for testing their lead product, OsteoActivator-P, in patients. OsteoActivator-P is a novel coated porcine collagen barrier membrane that will be placed on a dental defect to improve early bone formation.
About Osteo-Pharma
Osteo-Pharma is a Life Sciences company focused on the development of local treatments to improve the healing of bone fracture and defects. It’s proprietary OsteoActivator platform is used to develop biodegradable films, microspheres and coatings for implants with sustained release of small molecule drugs that enhance bone formation while simultaneously inhibiting bone resorption. The company is currently in mid-stage pre-clinical development for various projects and will start its first dental clinical trial in mid-2021.